Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Leukocyte reduction in blood component therapy.

T A Lane1, K C Anderson, L T Goodnough

  • 1UCSD School of Medicine, Department of Pathology, La Jolla 92093.

Annals of Internal Medicine
|July 15, 1992
PubMed
Summary

Leukocyte reduction in blood transfusions prevents adverse effects like febrile reactions and alloimmunization. Using leukocyte-reduced components is crucial for patients needing long-term transfusion support, minimizing risks and improving outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A high-throughput platform for biophysical antibody developability assessment to enable AI/ML model training.

mAbs·2025
Same author

Retraction Note: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide.

Leukemia·2024
Same author

Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials.

Seminars in hematology·2023
Same author

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Leukemia·2019
Same author

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

Leukemia·2018
Same author

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Leukemia·2017

Area of Science:

  • Transfusion Medicine
  • Immunology
  • Hematology

Background:

  • Passenger leukocytes in cellular blood components are a primary cause of transfusion-related adverse effects.
  • These effects include alloimmunization to human leukocyte antigen (HLA) and leukocyte-specific antigens, febrile transfusion reactions, platelet refractoriness, and transfusion-associated cytomegalovirus (CMV) infection.

Purpose of the Study:

  • To review methods for preventing or minimizing adverse effects from passenger leukocytes in transfused cellular blood components.
  • To identify patient groups at higher risk for these transfusion-related adverse effects.

Main Methods:

  • Systematic review of English-language articles on transfusion medicine.
  • Analysis of original reports detailing the pathogenesis of leukocyte-induced adverse effects and the impact of leukocyte-reduced blood components.

Related Experiment Videos

  • Evaluation of patient data, leukocyte reduction techniques, and outcomes such as alloimmunization, febrile reactions, and platelet refractoriness.

    • Main Results:

    • Passenger leukocytes are the main cause of alloimmunization, leading to febrile reactions, platelet refractoriness, and acute lung injury.
    • Leukocytes also transmit transfusion-associated cytomegalovirus (CMV) infection.
    • Technological advances allow leukocyte reduction to <10^7 per transfusion, suggesting this can minimize febrile reactions and alloimmunization, and prevent CMV transmission.

    Conclusions:

    • Leukocyte reduction using third-generation filters is indicated for patients requiring long-term transfusion support to prevent febrile reactions and alloimmunization.
    • Leukocyte-depleted transfusions are also recommended to prevent or delay platelet refractoriness.
    • This strategy is vital for improving transfusion safety and patient outcomes in specific at-risk populations.